PA
SNDX icon

Profund Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Profund Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
49,412
-6,492
-12% -$135K 0.03% 329
2026
Q1 		$1.31M Sell
55,904
-4,134
-7% -$89.8K 0.05% 278
2025
Q4 		$1.26M Buy
60,038
+29,221
+95% +$510K 0.04% 294
2025
Q3 		$474K Buy
30,817
+4,178
+16% +$54.7K 0.02% 534
2025
Q2 		$249K Sell
26,639
-8,842
-25% -$97.3K 0.01% 789
2025
Q1 		$436K Buy
35,481
+933
+3% +$13.2K 0.02% 519
2024
Q4 		$457K Buy
34,548
+387
+1% +$6.62K 0.02% 565
2024
Q3 		$658K Buy
34,161
+930
+3% +$19.2K 0.02% 427
2024
Q2 		$682K Sell
33,231
-25,016
-43% -$524K 0.03% 402
2024
Q1 		$1.39M Sell
58,247
-6,935
-11% -$155K 0.05% 264
2023
Q4 		$1.41M Buy
65,182
+17,140
+36% +$263K 0.06% 256
2023
Q3 		$698K Sell
48,042
-12,799
-21% -$242K 0.04% 375
2023
Q2 		$1.27M Buy
60,841
+8,236
+16% +$171K 0.07% 260
2023
Q1 		$1.11M Buy
+52,605
New +$1.31M 0.07% 276

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Profund Advisors's SNDX Position: Q2 2026 in Review

Profund Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q2 2026, selling an estimated $135K and leaving 49,412 shares worth $1.08M. The position accounts for 0.03% of the portfolio, ranked #329.

Profund Advisors first reported a position in SNDX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.41M in Q4 2023. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Profund Advisors held 49,412 shares of Syndax Pharmaceuticals worth $1.08M as of Q2 2026.
  • Profund Advisors sold 6,492 Syndax Pharmaceuticals shares in Q2 2026, an estimated $135K.
  • Syndax Pharmaceuticals made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #329 holding.
  • Profund Advisors first reported a position in Syndax Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Syndax Pharmaceuticals position peaked at $1.41M in Q4 2023.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.